TEPOTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS: A US COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Yang, M. [1 ]
Sachdev, R. [2 ]
Stargardter, M. [2 ]
Tosh, J. [3 ]
Vioix, H. [4 ]
机构：
[1] EMD Serono, Rockland, MA USA
[2] Evidera, Bethesda, MD USA
[3] Evidera, London, England
[4] Merck KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE160
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan
    Lee, Wei-Ling
    Chou, Wan-Hsuan
    Chang, Wei-Pin
    Chang, Tsung-Wei
    Kuo, Chun-Nan
    Chang, Wei-Chiao
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2024, 32 (04)
  • [42] Cost-effectiveness of smoking cessation in patients with non-small cell lung cancer
    Kunde, Katharina
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2023, 28 (04): : 150 - 151
  • [43] Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review
    Bearz, Alessandra
    Berretta, Massimiliano
    Tirelli, Umberto
    CURRENT CANCER DRUG TARGETS, 2018, 18 (05) : 405 - 409
  • [44] Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice
    Ho, C.
    Wong, S.
    Hatswell, A.
    Slater, R.
    Vioix, H.
    Chouaid, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1087 - S1088
  • [45] Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial.
    Reinmuth, Niels
    Mazieres, Julien
    Popat, Sanjay
    Paz-Ares, Luis G.
    Hook, Emma S.
    Hatswell, Anthony
    Vlassak, Soetkin
    Johne, Andreas
    Vioix, Helene
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysis
    Zhao, Ziying
    Zeng, Xiaohui
    Zhou, Zhen
    Liu, Qiao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (09)
  • [47] A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Paik, P.
    Cortot, A.
    Felip, E.
    Sakai, H.
    Mazieres, J.
    Horn, L.
    Griesinger, F.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Veillon, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
  • [48] MANAGING SIDE EFFECTS OF TEPOTINIB TREATMENT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING MET EXON 14 SKIPPING: EXPERT GUIDANCE BASED ON CLINICAL EXPERIENCE
    Alexander, Terri
    Ahn, Linda
    Berghoff, Karin
    Vlassak, Soetkin
    Lemmens, Liesbeth
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [49] Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
    Le, X.
    Martinalbo, J.
    Holynskyj, A.
    Rhodes, W. C.
    Wu, W-H.
    Kim, J.
    Pretre, V.
    Ye, F.
    Morrissette, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S988 - S988
  • [50] A PROPENSITY SCORE-BASED COMPARISON OF TEPOTINIB VERSUS IMMUNOTHERAPY WITH/WITHOUT CHEMOTHERAPY, USING REAL-WORLD DATA IN PREVIOUSLY UNTREATED MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
    Hook, E.
    Batteson, R.
    Christopoulos, P.
    Guisier, F.
    Ekman, S.
    Hatswell, A.
    Vioix, H.
    VALUE IN HEALTH, 2023, 26 (12) : S44 - S44
12345